Public disclosures

Reynolds Cameron John

Company insiders · President and CEO · Director · VOLITIONRX LTD

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
1
Buy lines
1
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-111

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Reynolds Cameron John

President and CEO · Director · VOLITIONRX LTD

VNRX

VOLITIONRX LTD

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 185781 · SEC code covers open-market or private transactions · On April 28, 2026, the Issuer effected a one-for-20 reverse stock split of its issued and outstanding common stock and made proportionate retroactive adjustments to its outstanding equity awards to the extent required including with respect to then-outstanding RSUs (the "Reverse Split"). No fractional shares were issued in connection with the Reverse Split, and each holder who otherwise would have been entitled to receive a fractional share received one whole share of common stock in lieu of such fractional share. Accordingly, the amount of securities beneficially owned directly and indirectly in column 5 of Table 1 has been adjusted to reflect the impact of the Reverse Split.

2026-11-192026-11-20

≈ $6,848.00

40,000 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement